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ABSTRACT
Objective: Breast cancer is the most diagnosed cancer in women, which leads to death in a lot of women with breast cancer. The major risk factors 
associated with breast cancer risk related to family history, age, clinical history, lifestyle factors, long-period hormonal exposure, and single nucleotide 
polymorphisms in many genes showed possible links with breast cancer incidence risk in different people populations. Our study aimed to figure out 
the correlation between smoking, lodging and family history, and other factors with the risk of breast cancer.
Methods: Blood sample from female patients with breast cancer and healthy individuals were collected and subjected to tetra-amplification refractory 
mutation system–polymerase chain reaction (T-ARMS-PCR) technique for −607 C/A mutation of an interleukin (IL-18) gene and SPSS 18 software 
analyzed the results statically.
Results: Results showed no association between lodging and smoking with risk of breast cancer, (p>0.05), while the association between the risk and 
family history were obvious (p<0.05).
Conclusion: The results obtained by T-ARMS-PCR technique did not show the association between −607 C/An alternation of IL-18 gene and breast 
cancer (p>0.05) in the individuals examined in our study.
Keywords: Interleukin-18, Gene, Polymorphism, Tetra-amplification refractory mutation system–polymerase chain reaction, Mutations.
INTRODUCTION
Breast cancer begins when normal cells in the portions of breast multiply 
and divide to compose new cells, as the body needs. When regular 
cells grow obsolete or damaged, it dies, and the new cells replace it [1]. 
Occasionally, this operation goes erroneous. New cells compose once 
the body does not need them, and obsolete or damaged cells don not die 
duly. The accumulation of additional cells often composes a mass of tissue 
named a lump, growth, or tumor [1,2]. It is the most frequently diagnosed 
cancer in women and the cause that leads to cancer death in women.
The main risk factors associated with breast cancer risk has been 
related to family history, age, clinical history, lifestyle factors, late first 
pregnancy, and long-period hormonal exposure [3].
Raised expression of a number of genes due to single nucleotide 
polymorphisms (SNPs) increases the breast cancer incidence risk [4,5]. 
Many researchers have demonstrated that genetic polymorphisms 
are one of the reasons for the individual difference in the incidence of 
cancer [6].
Interleukin-18 (IL), a protein of the IL-1 family, can activate immune cells 
without or with IL-12 [7]. IL-18 can organize both adaptive and innate 
immune responses during its impacts on natural killer (NK) cells, dendritic 
cells, monocytes, B-cells, and T-cells [8]. It can increase the immune 
resistance toward tumor cells by energizing and stimulating the interferon 
(IFN-γ) production and therefore has a key role in Th1 response [8].
The human has IL-18 gene is situated on chromosome 11q22.2-22.3 
and composed of “6 exons and 5 introns” [9]. Three types of SNPs of 
the IL-18 gene in the promoter nucleotides was determined, called 
−137 G/C (rs187238), −656 G/T or rs1946518, and −607 C/A or 
rs1946519 [9]. IL-18 gene polymorphisms have shown correlation with 
different diseases such as oral cancer [10], colorectal cancer [11], thyroid 
cancer [12], bladder cancer [13], lung cancer [14]. and nasopharyngeal 
carcinoma [15]. On the other hand, other studies found there were no 
correlations between −607 C/A polymorphism of IL-18 gene and head 
and neck squamous cell carcinoma [16] or breast cancer risk [17]. 
Therefore, our study aims to determine whether there is a link between 
−607 C/A polymorphism of IL-18 gene with the risk of breast cancer or 
in our Iraqi sample of the study.
METHODS
Blood samples were collected from 34 females with breast cancer who 
admitted AD Diwaniyha Teaching University Hospital and 21 healthy 
females as control group through study, groups were illustrated in 
Fig. 1.
IL-18 (rs1946518) polymorphisms were detected using (T-ARMS PCR), 
as mentioned by Taheri et al. [17]. Polymerase chain reaction (PCR) 
was performed using commercially available PCR premix (AccuPower 
PCR PreMix, BIONEER, South Korea) as described by manufacturer; 1 µl 
template DNA (50 ng/µl), 1 µl of each primer (10 µM), and 15 µl PCR-
water were added to each reaction. The PCR program were as follows: 
Initial denaturation at 95°C/5 minutes followed by 35 cycles; consisting 
of denaturation at 95°C/30 seconds, annealing at 54°C/30 seconds, and 
extension at 72°C/45 seconds with a final extension at 72°C/5 minutes. 
The PCR products were analyzed by 1.5% agarose gel electrophoresis 
containing 0.5 µg/ml ethidium bromide and visualized under ultraviolet 
light. Product sizes were 208 bp for the C allele, 278 bp for the A allele, 
and 440 bp for control band.
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The statistical analysis between the alleles frequencies and genotype 
distributions of the groups were confirmed by the binary logistic 
regression at p<0.05 using the SPSS 18 software. The correlation 
between some variables as a risk factor and breast cancer susceptibility 
were conducted by t-test at p<0.05 and as a significant variation.
RESULTS AND DISCUSSION
The variables and the risk of breast cancer
The risk of breast cancer incidence with some variables such as 
smoking, lodging, and family history was estimated by the odd ratio and 
their confidence interval at p<0.05, the matching in ages between cases 
and controls were demonstrated by p value as shown in the Table 2.
In our study and as obvious from the results, there was not an 
association between lodging and smoking with risk of breast cancer 
occurrence (p value were higher than 0.05). While the association 
between the risk and family history were obvious (p<0.05), the same 
result obtained from a previous study [18].
Association between polymorphisms and risk of breast cancer
Our study examined the correlation between 2124 and −607 C/A 
(rs1946519) polymorphisms of IL-18 gene with breast cancer risk. 
The study was performed using tetra-amplification refractory mutation 
system–PCR (T-ARMS-PCR) [17]. Fig. 2 shows the PCR product of IL-18 
gene on agarose gel using (100 bp DNA Ladder), the results were shown 
the bands of extracted DNA samples for the four groups (G1, G2, G3 and 
G4), and the PCR product is C allele (208 bp), an allele (278 bp) and 
control band (440 bp).
Genotype frequencies and allele distributions
Related individuals to patients group (G2) with control group (G1)
The genotype frequencies and allelic distributions of –607 C/A 
polymorphism of IL-18 in related (G2) and control (G1) groups were 
summarized in Table 3. The outcomes demonstrate that the frequency 
of CC is 6.7%, AC is 80%, and AA is 13.3% in G1. The frequency of CA 
−607 polymorphism in G2 were 16.6% for CC, 83.3% for AC, and 0% for 
AA. There were no significantly difference in −607 C/A polymorphism 
of IL-18 between G2 and G1 (p=0.488). As shown in Table 3 in G1, an 
allele frequency was 53.3% and the C allele frequency were 46.7%, 
and in the G2 the frequencies were 58.33% for C allele and 41.66% for 
An allele. The frequency of allele was not different between G1 and G2 
(p=0.496).
Treated (G3) with control (G1) groups
The genotype frequencies with allele distributions of −607 C/A alternation 
of IL-18 in treated (G3) and control (G1) groups explained in Table 4. 
The results show that the frequency of CC is 6.7%, AC is 80%, and AA is 
13.3% in G1. The frequency of CA −607 alternation in G3 were 23.8% for 
CC, 71.4% for AC, and 4.8% for AA. There were not significantly difference 
in −607 C/A polymorphism of IL-18 between G3 and G1.As shown in 
Table 3 in G1, an allele frequency were 53.3% and the C allele frequency 
were 46.7%, and in the G3 the frequencies were 59.5% for an allele 
and 41.66 % for C allele. Logistic regression analyses indicated that the 
Fig. 1: Study groups and subgroups
Fig. 2: Electrophoresis pattern of tetra-amplification refractory 
mutation system–polymerase chain reaction products for 
polymorphisms for interleukin-18 gene −607 C/A (rs1946519). 
M: 100bp DNA Ladder, Lane 1: to G4 (Untreated group), Lane 2-9: 
G3 (Treated), Lane 10: G2 (Related-sister of the patient No. 9) and 
Lane 11, 12: G1 (Control)
Primers Sequence 5’ → 3’ Temperature (°C)
Forward outer primer CCTACAATGTTACAACACTTAAAAT 53
Reverse outer primer ATAAGCCCTAAATATATGTATCCTTA
Forward inner primer GATACCATCATTAGAATTTTGTG
Reverse inner primer GCAGAAAGTGTAAAAATTATCAA
T-ARMS-PCR: Tetra-amplification refractory mutation system–polymerase chain reaction, IL-18: Interleukin-18
Table 2: Clinical characteristic and breast cancer risk




OR (95% CI) p value
Lodging
Urban 28 (60.9) 8 (53.33) 0.563 (0.174-1.821) 0.334
Rural 18 (39.1) 7 (46.77)
Smoking
Non smoker 43 (93.5) 15 (100) 1.070 (0.991-1.155) 0.31
Smoker 3 (6.5) 0 (0)
Family history
Without family history 34 (71.9) 15 (100) 1.353 (1.140-1.606) 0.027*
With family history 12 (26.1) 0 (0)
Age (mean±SE) 46.73±3.54 47.93±3.05 0.988
*The value is statically significant, G3 treated, G4 untreated, G1 control. SE: Standard error, OR: Odd ratio, CI: Confidence interval
Table 1: IL-18 –607 C/A (rs1946518) T-ARMS-PCR primers
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−607 C/AAC and CC genotypes did not correlate with breast cancer risk 
in comparison with the AA genotype (p=0.476 and p=0.161). Alike results 
noticed when comparing the C allele with the reference A allele (p=0.233).
Untreated (G4) with control (G1) groups
The genotype frequencies and allele distributions of −607 C/A 
polymorphism of IL-18 in untreated (G4) and control (G1) groups 
were shown in Table 5. The results show that the frequency of CC is 
6.7%, AC is 80%, and AA is 13.3% in G1. The frequency of CA −607 
polymorphism in G4 were 72.7% for AC, 9.1% for AA, and 18.2% for 
CC. There was no significantly difference in −607 C/A polymorphism of 
IL-18 between G4 and G1 (p>0.05). As shown in Table 4 in G1, An allele 
frequency was 53.3% and the C allele frequency were 46.7%, and in 
the G4 the frequencies were 40.9% for An allele and 59.1% for C allele. 
Logistic regression analyses confirmed that the “−607 C/AAC and CC 
genotypes have not associated with breast cancer risk compared with 
the AA genotype (p=0.826 and p=0.711). Alike results were noticed as 
comparing the C allele with the reference A allele (p=0.574).”
Untreated (G4) with treated (G3)
The genotype frequencies and allele distributions of −607 C/A alternation 
of IL-18 in untreated (G4) and control (G1) groups were shown in Table 6. 
The results show that the frequencies were 23.8% for CC, 71.4% for 
AC, and 4.8% for AA in G3. The frequency of CA −607 polymorphism 
in G4 were 18.2% for CC, 72.7% for AC, and 9.1% for AA. There was no 
significantly difference in −607 C/A polymorphism of IL-18 between G4 
and G3 (p>0.05). As shown in Table 5 in G3, an allele frequency was 59.5% 
and the C allele frequency were 40.5%, and in the G4 the frequencies were 
40.9% for An allele and 59.1 % for C allele. Logistic regression analyses 
indicated so as to the −607C/AAC and “CC” genotypes were compared 
with the AA genotype there was an insignificant difference (p=0.467 and 
p=0.368). In a similar way, the results were registered when comparing the 
“C allele with the reference A allele (p=0.621).”
DISCUSSION
The family background of breast cancer occurrence is one of the most 
significant risk factors for the progression of breast cancer [19]. Aside from 
age, women with one influenced the first-degree relative are approximately 
twice as likely to promote breast cancer compared with women who have 
no influenced relatives, and risks are higher when more than one first-
degree relative is influenced or the relative is youthful at diagnosis [19,20].
In our study and as obvious from the results, there is an 
association between family background and the risk of breast 
Table 3: The genotypes and allelic distribution of IL-18 gene−607 C/A (rs1946519) in G2 and G1 groups




χ2a pa OR (95% CI)b pb
AA 2 (13.3) 1.433 0.488 1.0ref (1.0ref)
AC 12 (80.0) 5 (83.3) 0.000 (0.000)
CC 1 (6.7) 1 (16.7) 0.000 (0.000) 0.488
A allele 16 (53.3) 5 (41.66) 0.468 0.494 1.0ref (1.0ref)
C allele 14 (46.7) 7 (58.33) 1.600 (0.413-6.193) 0.496
aValue for genotype distribution, bValue was calculated as relative to subjects with the A/A genotypes and An allele. IL-18: Interleukin-18
Table 4: The genotypes and allele distribution of IL-18 polymorphism in G3 and G1




χ2a pa OR (95% CI)b pb
AA 2 (13.3) 1 (4.8) 2.58 0.275 1.0ref (1.0ref)
AC 12 (80.0) 15 (71.4) 0.400 (0.320-4.960) 0.476
CC 1 (6.7) 5 (23.8) 0.100 (0.004-2.504) 0.161
A allele 16 (53.3) 25 (59.5) 1.434 0.231 1.0ref (1.0ref)
C allele 14 (46.7) 17 (40.5) 1.786 (0.689-4.631) 0.233
aValues for genotype distribution, bValue was calculated as relative to subjects with the A/A genotypes and An allele. IL-18: Interleukin-18
Table 5: The genotypes and allele distribution of IL-18 polymorphism in G4 and G1




χ2a pa OR (95% CI)b pb
AA 2 (13.3) 1 (9.1) 0.138 0.933 1.0ref (1.0ref)
AC 12 (80.0) 7 (72.2) 0.750 (0.580-9.719) 0.826
CC 1 (6.7) 2 (18.2) 0.500 (0.013-19.562) 0.711
A allele 16 (53.3) 9 (40.9) 0.316 0.574 1.0ref (1.0ref)
C allele 14 (46.7) 13 (59.1) 1.371 (0.455-4.136) 0.574
aValue of genotype distribution, bValue were calculated as relative to subjects with the A/A genotypes and An allele. IL-18: Interleukin-18
Table 6: The genotypes and allele distribution of IL-18 polymorphism in G4 and G3




χ2a pa OR (95% CI)b pb
AA 1 (4.8) 1 (9.1) 1.088 0.581 1.0ref (1.0ref)
AC 15 (71.4) 7 (72.2) 0.533 (0.029-9.708) 0.476
CC 5 (23.8) 2 (18.2) 0.200 (0.006-6.664) 0.368
A allele 25 (59.5) 9 (40.9) 0.243 0.622 1.0ref (1.0ref)
C allele 17 (40.5) 13 (59.1) 0.768 (0.269-2.190) 0.621
aValues about genotype distribution, bCalculated as relative to subjects with the A/A genotypes and An allele. IL-18: Interleukin-18
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cancer occurrence, the same result obtained from a previous 
study [18].
Our current study aims to identify the effect of IL-18 −607 C/A mutation 
on the predisposition of breast cancer in our population. We found no 
correlation between IL-18 −607 C/A polymorphism and predisposition 
to breast cancer. This result similar to a previous study [17].
IL-18 can be organized both adaptive and innate immune responses 
during its impacts on NK cells, dendritic cells, monocytes, B-cells, and 
T-cells [8]. It can raise the immune protection against cancer cells by 
energizing and stimulating the IFN-γ creation and therefore has a key 
role in Th1 response [8]. It has been made known that IL-18 has a major 
role in the progression of the tumor. IL-18 expression and serum level 
have been shown to elevate in different cancers in the blood stream of 
metastatic patients compared to healthy controls and patients with no 
metastasis [21]. Because of the double roles of IL-18 expression and 
serum level in both tumor metastasis and drug resistance, IL-18 may 
denote a helpful drug target for therapy of breast cancer [22]. It was 
clear that two SNPs in the promoter area of the IL-18 gene organized 
the gene expression levels at the transcriptional stage and changed 
the IL-18 production level [17]. The alteration from the “C allele to the 
“A” allele at site −607C/A and at site −137 G/C alternation from the G 
allele to the C allele in the (promoter area) were prophesied to be the 
molecular factor linking sites for the cyclic adenosine monophosphate 
responsive element between protein and H4TF-1 factor, respectively 
in addition, polymorphisms of the two positions have been correlated 
with the activity of IL-18 gene promoter transcription, which can 
impact the IL-18 expression and, may be, of IFN-γ; these changes in 
alleles, potentially be the essential mechanism of IL-18 involvement 
in different diseases [23,24]. IL-18 polymorphism has been shown 
correlated with different diseases such as oral cancer [10], colorectal 
cancer [11], thyroid cancer [12], bladder cancer [13], lung cancer [14], 
and nasopharyngeal carcinoma” [15].
CONCLUSION
Our study showed no significant correlation between −607 C/A 
polymorphism of IL-18 gene and breast cancer risk in the Iraqi 
individuals subjected to this study.
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